Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pazopanib in FGFR2-altered Refractory Solid Tumors
NCT02450136Phase 2Completed
- Sponsor
- Samsung Medical Center
- Start
- Oct 2015
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pazopanib in solid tumor, sponsored by Samsung Medical Center. Started Oct 2015; status: completed.
02
Drugs
pazopanib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02450136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02450136.